المؤلفون: Tjokrowidjaja A; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia. Electronic address: angelina.tjokrowidjaja@sydney.edu.au., Friedlander M; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia., Lord SJ; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; School of Medicine, The University of Notre Dame, Sydney, NSW 2007, Australia., Asher R; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia., Rodrigues M; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France., Ledermann JA; UCL Cancer Institute, University College London, London WC1E 6DD, Great Britain, UK., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Oza AM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada., Bruchim I; Gynecologic Oncology Division, Hillel Yaffe Medical Center, Technion Institute of Technology, Haifa, Israel., Huzarski T; Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland., Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh, UK., Harter P; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany., Vergote I; Department of Oncology, KU Leuven - University of Leuven, B-3000 Leuven, Belgium; Division of Gynaecological Oncology, University Hospitals Leuven, B-3000 Leuven, Belgium., Scott CL; Walter and Eliza Hall Institute of Medical Research, Stem Cells, and Cancer, University of Melbourne, Melbourne, Victoria, Australia., Meier W; Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Düsseldorf, Germany; University Hospital Düsseldorf, Düsseldorf, Germany., Shapira-Frommer R; Sheba Medical Center, Ramat-Gan, Israel., Milenkova T; AstraZeneca, Cambridge, United Kingdom., Pujade-Lauraine E; Université Paris Descartes, Paris, France; ARCAGY-GINECO, Australia., Gebski V; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia., Lee CK; National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Sep; Vol. 154, pp. 190-200. Date of Electronic Publication: 2021 Jul 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Genes, BRCA1* , Genes, BRCA2* , Mutation* , Nomograms*, Neoplasm Recurrence, Local/*drug therapy , Ovarian Neoplasms/*drug therapy , Phthalazines/*toxicity , Piperazines/*toxicity, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Prognosis ; Progression-Free Survival

المؤلفون: Lee CK; St George Hospital, Sydney, NSW, Australia. chee.lee@ctc.usyd.edu.au.; National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Sydney, NSW, Australia. chee.lee@ctc.usyd.edu.au., Scott C; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Royal Melbourne Hospital, Melbourne, VIC, Australia., Lindeman GJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; The Royal Melbourne Hospital, Melbourne, VIC, Australia., Hamilton A; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Lieschke E; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia., Gibbs E; National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Sydney, NSW, Australia., Asher R; National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Sydney, NSW, Australia., Badger H; Breast Cancer Trials Australia & New Zealand, Newcastle, NSW, Australia., Paterson R; Breast Cancer Trials Australia & New Zealand, Newcastle, NSW, Australia., Macnab L; Breast Cancer Trials Australia & New Zealand, Newcastle, NSW, Australia., Kwan EM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Francis PA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Boyle F; Breast Cancer Trials Australia & New Zealand, Newcastle, NSW, Australia.; The Mater Hospital, North Sydney, NSW, Australia., Friedlander M; Prince of Wales Hospital, Sydney and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.

المصدر: British journal of cancer [Br J Cancer] 2019 Feb; Vol. 120 (3), pp. 279-285. Date of Electronic Publication: 2019 Jan 17.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cyclophosphamide/*administration & dosage , Ovarian Neoplasms/*drug therapy , Phthalazines/*administration & dosage , Piperazines/*administration & dosage , Triple Negative Breast Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Cyclophosphamide/adverse effects ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Germ-Line Mutation/genetics ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Phthalazines/adverse effects ; Piperazines/adverse effects ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology

المؤلفون: Friedlander M; Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia.; The Prince of Wales Clinical School, University of New South Wales, UNSW, New South Wales, Australia., Shannon C; Mater Cancer Care Centre, South Brisbane, Queensland, Australia., Goh J; Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.; The University of Queensland, St Lucia, Queensland, Australia., Scott C; Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Royal Melbourne Hospital, Parkville, Victoria, Australia., Mileshkin L; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; The University of Melbourne, Melbourne, Victoria, Australia.

المصدر: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Dec; Vol. 14 (6), pp. 459-464. Date of Electronic Publication: 2018 Nov 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-7563 (Electronic) Linking ISSN: 17437555 NLM ISO Abbreviation: Asia Pac J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Capsules/*administration & dosage , Neoplasms/*drug therapy , Phthalazines/*therapeutic use , Piperazines/*therapeutic use , Practice Guidelines as Topic/*standards , Tablets/*administration & dosage, Dose-Response Relationship, Drug ; Humans ; Phthalazines/pharmacokinetics ; Piperazines/pharmacokinetics ; Tissue Distribution

المؤلفون: Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia. Michael.friedlander@health.nsw.go.au., Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA., Gourley C; Cancer Research UK Edinburgh Centre, Western General Hospital, Edinburgh, UK., du Bois A; Kliniken Essen Mitte, Essen, Germany., Vergote I; University of Leuven, Leuven Cancer Institute, Leuven, Belgium., Rustin G; Mount Vernon Hospital, Northwood, UK., Scott C; Royal Melbourne Hospital, Parkville, VIC, Australia., Meier W; University of Düsseldorf, Düsseldorf, Germany., Shapira-Frommer R; Chaim Sheba Medical Center, Tel Hashomer, Israel., Safra T; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Matei D; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Shirinkin V; Orenburg Regional Clinical Oncological Dispensary, Orenburg, Russia., Selle F; Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.; GINECO Group, Paris, France., Fielding A; AstraZeneca, Cambridge, UK.; AstraZeneca, Gaithersburg, MD, USA., Lowe ES; AstraZeneca, Gaithersburg, MD, USA., McMurtry EL; AstraZeneca, Cambridge, UK., Spencer S; AstraZeneca, Cambridge, UK., Rowe P; AstraZeneca, Cambridge, UK., Mann H; AstraZeneca, Cambridge, UK., Parry D; AstraZeneca, Cambridge, UK., Ledermann J; University College London Cancer Institute, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2018 Oct; Vol. 119 (9), pp. 1075-1085. Date of Electronic Publication: 2018 Oct 24.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Cystadenocarcinoma, Serous/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Ovarian Neoplasms/*drug therapy , Phthalazines/*administration & dosage , Piperazines/*administration & dosage, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Capsules ; Cystadenocarcinoma, Serous/genetics ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Maintenance Chemotherapy ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/genetics ; Ovarian Neoplasms/genetics ; Phthalazines/adverse effects ; Piperazines/adverse effects ; Platinum/administration & dosage ; Platinum/therapeutic use ; Treatment Outcome ; Young Adult

المؤلفون: Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia. Electronic address: m.friedlander@unsw.edu.au., Gebski V; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia., Gibbs E; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia., Davies L; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Nuffield Department of Population Health, University of Oxford, Oxford, UK., Bloomfield R; AstraZeneca, Cambridge, UK., Hilpert F; Jerusalem Hospital, Hamburg, Germany., Wenzel LB; University of California, Irvine, CA, USA., Eek D; AstraZeneca, Gothenburg, Sweden., Rodrigues M; Institut Curie, Paris, France., Clamp A; The Christie and University of Manchester, Manchester, UK., Penson RT; Harvard Medical School, Boston, MA, USA., Provencher D; University of Montreal, Montreal, QC, Canada., Korach J; Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel., Huzarski T; Pomeranian Medical University, Szczecin, Poland., Vidal L; Hospital Clinic, Barcelona, Spain., Salutari V; Policlinico Universitario Agostino Gemelli, Rome, Italy., Scott C; The Walter and Eliza Hall Institute of Medical Research, Parkville, VA, Australia., Nicoletto MO; Istituto Oncologico Veneto, Padova, Italy., Tamura K; National Cancer Center Hospital, Tokyo, Japan., Espinoza D; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia., Joly F; Centre François Baclesse, Caen, France., Pujade-Lauraine E; Université Paris Descartes, AP-HP, Paris, France.

المصدر: The Lancet. Oncology [Lancet Oncol] 2018 Aug; Vol. 19 (8), pp. 1126-1134. Date of Electronic Publication: 2018 Jul 17.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life*, Antineoplastic Agents/*therapeutic use , Carcinoma, Ovarian Epithelial/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Phthalazines/*therapeutic use , Piperazines/*therapeutic use, Adult ; Aged ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/mortality ; Female ; Humans ; Maintenance Chemotherapy/methods ; Middle Aged ; Mutation ; Progression-Free Survival ; Surveys and Questionnaires

المؤلفون: Friedlander M; Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia., Banerjee S; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK., Mileshkin L; Peter MacCallum Cancer Care Centre, Melbourne, Victoria, Australia., Scott C; Royal Melbourne Hospital, Parkville, Victoria, Australia., Shannon C; Mater Cancer Care Centre, Brisbane, Queensland, Australia., Goh J; Royal Brisbane and Women's Hospital, Herston (Brisbane), Queensland, Australia.

المصدر: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2016 Dec; Vol. 12 (4), pp. 323-331.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print Cited Medium: Internet ISSN: 1743-7563 (Electronic) Linking ISSN: 17437555 NLM ISO Abbreviation: Asia Pac J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*adverse effects , Antineoplastic Agents/*therapeutic use , Ovarian Neoplasms/*drug therapy , Phthalazines/*adverse effects , Phthalazines/*therapeutic use , Piperazines/*adverse effects , Piperazines/*therapeutic use, Female ; Humans ; Mutation ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/mortality ; Phthalazines/administration & dosage ; Piperazines/administration & dosage

المؤلفون: Ledermann JA; University College London, Cancer Research UK and UCL Cancer Trials Centre, 90 Tottenham Court Road, London W1T 4TJ, UK., Harter P; Kliniken Essen Mitte, Henricistraße 95, D-45136 Essen, Germany., Gourley C; University of Edinburgh Cancer Research UK Centre, MRC IGMM, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK., Friedlander M; UNSW Clinical School, Prince of Wales Hospital, High Street, Randwick, NSW 2031, Australia., Vergote I; University of Leuven, Herestraat 49, 3000 Leuven, Belgium., Rustin G; Mount Vernon Hospital, Rickmansworth Road, Northwood HA6 2RN, UK., Scott C; Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia., Meier W; Evangelisches Krankenhaus, Kirchfeldstraße 40, 40217 Düsseldorf, Germany., Shapira-Frommer R; Chaim Sheba Medical Center, Derech Sheba 2, Tel Hashomer 52621, Israel., Safra T; Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel., Matei D; Indiana University School of Medicine, 980 West Walnut Street, Indianapolis, IN 46202, USA., Fielding A; AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK., Bennett B; AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK., Parry D; AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK., Spencer S; AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK., Mann H; AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK., Matulonis U; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

المصدر: British journal of cancer [Br J Cancer] 2016 Nov 22; Vol. 115 (11), pp. 1313-1320. Date of Electronic Publication: 2016 Nov 08.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life*, Antineoplastic Agents/*therapeutic use , Ovarian Neoplasms/*drug therapy , Phthalazines/*therapeutic use , Piperazines/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Phthalazines/adverse effects ; Piperazines/adverse effects ; Placebos ; Young Adult

المؤلفون: Ledermann JA; UCL Cancer Institute, University College London and UCL Hospitals, London, UK. Electronic address: j.ledermann@ucl.ac.uk., Harter P; Kliniken Essen Mitte, Essen, Germany., Gourley C; University of Edinburgh Cancer Research UK Centre, Medical Research Council Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK., Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia., Vergote I; University of Leuven, Leuven, Belgium., Rustin G; Mount Vernon Hospital, Northwood, UK., Scott C; Royal Melbourne Hospital, Parkville, VIC, Australia., Meier W; Evangelisches Krankenhaus, Düsseldorf, Germany., Shapira-Frommer R; Chaim Sheba Medical Center, Tel Hashomer, Israel., Safra T; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Matei D; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Fielding A; AstraZeneca, Alderley Park, Macclesfield, UK., Spencer S; AstraZeneca, Alderley Park, Macclesfield, UK., Rowe P; AstraZeneca, Alderley Park, Macclesfield, UK., Lowe E; AstraZeneca, Gaithersburg, MD, USA., Hodgson D; AstraZeneca, Alderley Park, Macclesfield, UK., Sovak MA; AstraZeneca, Gaithersburg, MD, USA., Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA.

المصدر: The Lancet. Oncology [Lancet Oncol] 2016 Nov; Vol. 17 (11), pp. 1579-1589. Date of Electronic Publication: 2016 Sep 09.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Cystadenocarcinoma, Serous/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Ovarian Neoplasms/*drug therapy , Phthalazines/*therapeutic use , Piperazines/*therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Cystadenocarcinoma, Serous/mortality ; Double-Blind Method ; Female ; Humans ; Middle Aged ; Mutation ; Ovarian Neoplasms/mortality ; Phthalazines/adverse effects ; Piperazines/adverse effects

المؤلفون: Matulonis UA; Dana-Farber Cancer Institute, Boston, Massachusetts., Harter P; Kliniken Essen-Mitte, Essen, Germany., Gourley C; Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom., Friedlander M; Prince of Wales Hospital, Randwick, New South Wales, Australia., Vergote I; University of Leuven, Leuven, Belgium., Rustin G; Mount Vernon Hospital, Northwood, United Kingdom., Scott C; Royal Melbourne Hospital, Melbourne, Victoria, Australia., Meier W; Evangelical Hospital, Dusseldorf, Germany., Shapira-Frommer R; Chaim Sheba Medical Center, Tel Hashomer, Israel., Safra T; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Matei D; Indiana University School of Medicine, Indianapolis, Indiana., Fielding A; AstraZeneca, Macclesfield, United Kingdom., Spencer S; AstraZeneca, Macclesfield, United Kingdom., Parry D; AstraZeneca, Macclesfield, United Kingdom., Grinsted L; AstraZeneca, Macclesfield, United Kingdom., Ledermann JA; University College London, London, United Kingdom.

المصدر: Cancer [Cancer] 2016 Jun 15; Vol. 122 (12), pp. 1844-52. Date of Electronic Publication: 2016 Apr 08.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cystadenocarcinoma, Serous/*drug therapy , Ovarian Neoplasms/*drug therapy , Phthalazines/*administration & dosage , Piperazines/*administration & dosage , Poly(ADP-ribose) Polymerase Inhibitors/*administration & dosage, BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/mortality ; Data Interpretation, Statistical ; Disease Progression ; Double-Blind Method ; Female ; Germ-Line Mutation ; Humans ; Middle Aged ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Recurrence ; Survival Rate

المؤلفون: Valente LJ; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Aubrey BJ; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia; Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia., Herold MJ; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Kelly GL; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Happo L; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Scott CL; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Newbold A; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia., Johnstone RW; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia., Huang DC; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., Vassilev LT; Discovery Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA., Strasser A; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia. Electronic address: strasser@wehi.edu.au.

المصدر: Cell reports [Cell Rep] 2016 Mar 01; Vol. 14 (8), pp. 1858-66. Date of Electronic Publication: 2016 Feb 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE

مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic*, Antineoplastic Agents/*pharmacology , Apoptosis Regulatory Proteins/*genetics , Imidazoles/*pharmacology , Lymphoma/*drug therapy , Piperazines/*pharmacology , Tumor Suppressor Protein p53/*genetics , Tumor Suppressor Proteins/*genetics, Animals ; Apoptosis/drug effects ; Apoptosis Regulatory Proteins/metabolism ; CRISPR-Cas Systems ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p21/genetics ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; Disease Models, Animal ; Drug Resistance, Neoplasm/genetics ; Humans ; Lymphoma/genetics ; Lymphoma/metabolism ; Lymphoma/pathology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Proto-Oncogene Proteins c-mdm2/genetics ; Proto-Oncogene Proteins c-mdm2/metabolism ; Signal Transduction ; Tumor Suppressor Protein p53/agonists ; Tumor Suppressor Protein p53/metabolism ; Tumor Suppressor Proteins/metabolism